BioSpace News Archive

Elanco Animal Health Incorporated announced it has signed an agreement to divest the European Economic Area and UK rights to the Drontal® and Profender® product families from Bayer AG’s animal health business, to Vetoquinol SA, a French pharmaceutical company, for $140 million in an all-cash deal subject to customary post-closing adjustments.

AVEO Oncology (NASDAQ: AVEO) today announced the publication of results from a monotherapy trial of tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in patients with advanced, inoperable hepatocellular carcinoma (HCC) in the British Journal of Cancer.

Akorn, Inc., a leading specialty pharmaceutical company, announced it has reached an agreement with certain of its lenders to extend the standstill period.

Maternal factors, such as breast milk, have been shown to affect a baby’s development, and previous animal studies have determined that a carbohydrate, the oligosaccharide 2’FL found in maternal milk, positively influences neurodevelopment.

Further to my previous statements, as Chief Public Health Officer, I have assessed additional individuals in quarantine at Canadian Forces Base Trenton pursuant to an Emergency Order under the Quarantine Act and determined that they do not pose a risk of significant harm to public health.

Q-linea AB, announced that the company has entered into a worldwide exclusive partnership with Thermo Fisher Scientific for the commercialization of ASTar.

Encompass Health Corp. announces the opening of its 134th inpatient rehabilitation hospital, Encompass Health Rehabilitation Hospital of Murrieta..

Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 23, 2020 to file lead plaintiff applications in a securities class action lawsuit against Geron Corporation, if they purchased the Company’s shares between March 19, 2018 and September 26, 2018, inclusive.

Revolution Medicines, Inc. announced the pricing of its initial public offering of 14,000,000 shares of common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions.

Lexington Biosciences, Inc. has allowed the license with the Lawrence Berkeley National Laboratories, which was being used in the HeartSentry technology, to terminate due to non-payment of its minimum annual royalty fees which were due in August 2018 and August 2019..